Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Are More Bearish Than They Used To Be
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Mersana Therapeutics, Inc. (NASDAQ:MRSN) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.
对于Mersana Therapeutics,Inc. (NASDAQ:MRSN)的股东来说,今天的情况不太妙,分析师对今年的预测进行了大幅度的负面修正。营业收入和每股收益(每股收益)的预测都被下调,这表明分析师对业务非常失望。
Following the latest downgrade, the current consensus, from the ten analysts covering Mersana Therapeutics, is for revenues of US$26m in 2024, which would reflect a considerable 12% reduction in Mersana Therapeutics' sales over the past 12 months. Losses are presumed to reduce, shrinking 18% per share from last year to US$0.70. However, before this estimates update, the consensus had been expecting revenues of US$38m and US$0.62 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.
在最新的降级之后,Mersana Therapeutics的10位分析师的共识是,2024年收入为2600万美元,这表明Mersana Therapeutics过去12个月销售额大幅下降了12%。预计损失将减少,每股减少18%至0.70美元。然而,在这一估计更新之前,共识预计营业收入为3800万美元,每股损失为0.62美元。因此,情绪显然发生了明显的改变,分析师对今年的营收预期进行了显著的下调,同时加大了每股的损失预期。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240815/0-3433c4b91dd9fd6d35e7bbdb2f15dbb6-0-b72cd54c77ed57008823847b19c5df67.png/big)
There was no major change to the consensus price target of US$6.44, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts.
共识的目标股价仍为6.44美元,这表明尽管每股收益预测较低,业务仍在符合预期。
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that sales are expected to reverse, with a forecast 23% annualised revenue decline to the end of 2024. That is a notable change from historical growth of 16% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 23% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Mersana Therapeutics is expected to lag the wider industry.
我们还可以从更大的背景下看待这些预期,比如预测与过去的业绩相比如何,以及预测与行业内其他企业相比是否更为看好。我们应该指出,预计销售将反转,预计年化收入下降23%至2024年底。这是一个显著的变化,过去五年的历史增长率达16%。与我们的数据相比,该行业其他公司的总体预期年收入增长率为23%。因此,尽管其营业收入预计会收缩,但Mersana Therapeutics有可能落后于更广泛的行业。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Mersana Therapeutics. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Mersana Therapeutics after the downgrade.
这次降级最重要的一点是,共识预计今年的亏损将增加,这表明Mersana Therapeutics并非一切进展顺利。遗憾的是,他们还调低了营收预测,最新预测暗示该公司的销售增长将低于整个市场。我们也很惊讶地看到目标股价没有变化。然而,严峻的业务情况(如果预测准确!)可以成为股价的领先指标,因此我们不会因降级后对Mersana Therapeutics更为谨慎而责怪投资者。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Mersana Therapeutics going out to 2026, and you can see them free on our platform here.
话虽如此,在未来几年公司收益的长期轨迹比明年更重要。在Simply Wall St,我们对Mersana Therapeutics的分析师预测进行了全面的研究,可预测至2026年,您可以在我们的平台上免费查看这些预测。
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
跟踪管理层是购买还是销售,是寻找可能达到关键点的有趣公司的另一种方法,我们的免费公司列表由内部支持的增长公司组成。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。